RayKnowChina Research Map
Shortlist

QingdaoQingdao University

Affiliated Hospital of Qingdao University

青岛大学附属医院

Listed for 36 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Affiliated Hospital of Qingdao University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led
  3. Hepatocellular carcinoma肝细胞癌70 papers led
  4. Stomach cancer胃癌105 papers led7 open trials led
  5. Hepatoblastoma肝母细胞瘤6 papers led
  6. Retinoblastoma视网膜母细胞瘤2 papers led
  7. Chordoma脊索瘤1 paper led
  8. Osteosarcoma骨肉瘤16 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤7 papers led
  10. Neuroblastoma神经母细胞瘤9 papers led
  11. Ewing sarcoma尤文肉瘤2 papers led
  12. Multiple myeloma多发性骨髓瘤8 papers led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  14. Aplastic anaemia再生障碍性贫血7 papers led
  15. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  16. Haemophilia A血友病 A0 papers led
  17. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
  18. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  19. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病1 paper led1 open trial led
  20. IgG4-related diseaseIgG4相关性疾病2 papers led
  21. Myasthenia gravis重症肌无力2 papers led1 open trial led
  22. Moyamoya disease烟雾病2 papers led
  23. Wilson disease肝豆状核变性(Wilson 病)2 papers led
  24. Takayasu arteritis大动脉炎0 papers led
  25. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  26. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  27. Pompe disease庞贝病1 paper led
  28. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  29. IgA nephropathyIgA 肾病1 paper led
  30. Gaucher disease戈谢病1 paper led
  31. Niemann–Pick disease type C尼曼-匹克病 C 型1 paper led
  32. Primary biliary cholangitis原发性胆汁性胆管炎6 papers led
  33. Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led
  34. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
  35. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led
  36. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Beta thalassaemia, Fanconi anaemia, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Behçet disease, Alport syndrome, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Hereditary angioedema, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

1 hospital in Qingdao for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEBV & screening
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 332025

2 hospitals in Qingdao for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyMolecular markers & genomicsNeoadjuvant & combined treatment
Departments in papersRadiation oncologyMedical oncologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led8
  1. Development and validation of a prognostic model for first-line immunotherapy for metastatic esophageal squamous cell carcinoma.2026International immunopharmacology
  2. Comparing the Efficacy and Safety of IC-ICCRT-IO With CT-CCRT for Unresectable Locally Advanced ESCC: A Retrospective Analysis.2026Journal of immunotherapy (Hagerstown, Md. : 1997)
  3. The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous c2025BMC cancerFree full text
  4. Low Serum Interleukin-6 Levels Enhance the Efficacy of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.2025Cancer biotherapy & radiopharmaceuticals
  5. Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies.2025Pathology, research and practice
  6. A Recurrence Predictive Model for Node-negative Esophageal Squamous Cell Carcinoma After Upfront Esophagectomy.2024Seminars in thoracic and cardiovascular surgery
  7. A practical nomogram included hyperlipidemia for predicting lymph node metastasis in patients with superficial esophageal squamous cell carcinoma.2023MedicineFree full text
  8. Prognostic value of baseline 18F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy.2023Radiation oncology (London, England)Free full text
All its trials on ClinicalTrials.gov, any status4
  1. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  2. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  3. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  4. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)7
  1. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technologyarticle
  2. Abstract 2876: Spatial immune cell atlas predicts the sensitivity to neoadjuvant PD-1 blockade treatment combined with radiotherapy in resectable esophageal squamous cell carcinoma2024Cancer Researchconference-abstract
  3. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Researchconference-abstract
  4. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset
  5. MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway2022Figsharedataset
  6. 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas2021Annals of Oncologyarticle
  7. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 70 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
70
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 141420212022: 131320222023: 171720232024: 151520242025: 10102025

3 hospitals in Qingdao for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  2. Not yet recruiting
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07010588

    Age 18 years to 75 years (registered criteria)

    Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an

  3. Not yet recruiting
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07350070

    Age 18 years to 75 years (registered criteria)

    Led by Tongji Hospital; 4 listed hospitals as study sitesFuzhou, Jinan, Nanning, Qingdao, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led70
  1. Nanocarriers for the delivery of plant-extracted camptothecin derivatives and hepatocellular carcinoma treatment.2026Natural product research
  2. Conventional transarterial chemoembolization followed by irreversible electroporation for hepatocellular carcinoma.2025BMC cancerFree full text
  3. Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway.2025Cell death & diseaseFree full text
  4. Multi-omics spatial characteristics of CD8+TRM cells in hepatocellular carcinoma and immunotherapy response prediction.2025Frontiers in immunologyFree full text
  5. Identification of immunogenic cell death signature genes in hepatocellular carcinoma: from single-cell transcriptomics to in vitro mechanistic validation and comprehensive prognostic modeling with hundreds of machine learning algorithms.2025Frontiers in immunologyFree full text
  6. Tislelizumab plus tyrosine kinase inhibitors with TACE improves survival in unresectable hepatocellular carcinoma with clinical predictors and manageable safety.2025Frontiers in immunologyFree full text
  7. To determine the role of TRIT1 in the diagnosis, prognosis and immunoinvasion of liver hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  8. Integrated Analysis of Bulk RNA Sequencing, eQTL, GWAS, and Single-Cell RNA Sequencing Reveals Key Genes in Hepatocellular Carcinoma.2025Journal of cellular and molecular medicineFree full text
  9. Constructing a neural network model based on tumor-infiltrating lymphocytes (TILs) to predict the survival of hepatocellular carcinoma patients.2025PeerJFree full text
  10. Radiomics-based machine-learning method to predict extrahepatic metastasis in hepatocellular carcinoma after hepatectomy: a multicenter study.2025Scientific reportsFree full text
  11. Analysis of the factors influencing liver regeneration after hepatectomy in hepatocellular carcinoma patients and the relationship between liver regeneration and prognosis.2025Scientific reportsFree full text
  12. Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice.2024BMC cancerFree full text
  13. The role of liver cancer stem cells in hepatocellular carcinoma metastasis.2024Cancer biology & therapyFree full text
  14. Heterogeneity-induced NGF-NGFR communication inefficiency promotes mitotic spindle disorganization in exhausted T cells through PREX1 suppression to impair the anti-tumor immunotherapy with PD-1 mAb in hepatocellular carcinoma.2024Cancer medicineFree full text
  15. Letter 2 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma".2024Clinical and molecular hepatologyFree full text
  16. Textbook outcome of laparoscopic hepatectomy in the context of precision surgery: A single center experience.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  17. GCNT3 regulated MUC13 to promote the development of hepatocellular carcinoma through the GSK3β/β-catenin pathway.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  18. ENG is a Biomarker of Prognosis and Angiogenesis in Liver Cancer, and Promotes the Differentiation of Tumor Cells into Vascular ECs.2024Frontiers in bioscience (Landmark edition)
  19. Global research trends in the tumor microenvironment of hepatocellular carcinoma: insights based on bibliometric analysis.2024Frontiers in immunologyFree full text
  20. The role of RNA modifications in hepatocellular carcinoma: functional mechanism and potential applications.2024Frontiers in immunologyFree full text
  21. Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.2024Frontiers in immunologyFree full text
  22. Base editing of the mutated TERT promoter inhibits liver tumor growth.2024Hepatology (Baltimore, Md.)
  23. Hypoxic tumour-derived exosomal miR-1290 exacerbates the suppression of CD8+ T cells by promoting M2 macrophage polarization.2024Immunology
  24. Integrated Single Cell Analysis Reveals An Atlas of Tumor Associated Macrophages in Hepatocellular Carcinoma.2024Inflammation
  25. Stimulus Responsive Nanocarrier for Enhanced Antitumor Responses Against Hepatocellular Carcinoma.2024International journal of nanomedicineFree full text
  26. Multiomics Analysis of Interleukin-21 as a Potential Immunologic and Biomarker in Hepatocellular Carcinoma.2024Journal of immunotherapy (Hagerstown, Md. : 1997)
  27. Safety and Efficacy of CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma.2023Academic radiology
  28. Characteristic of molecular subtypes based on PANoptosis-related genes and experimental verification of hepatocellular carcinoma.2023AgingFree full text
  29. Analysis of the impact of fatty acid metabolism on immunotherapy for hepatocellular carcinoma.2023Annals of hepatology
  30. Tumor-stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma.2023BMC cancerFree full text
  31. Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center.2023BMC gastroenterologyFree full text
  32. Machine learning-based radiomics analysis of preoperative functional liver reserve with MRI and CT image.2023BMC medical imagingFree full text
  33. FOXM1 augments sorafenib resistance and promotes progression of hepatocellular carcinoma by epigenetically activating KIF23 expression.2023Biochemical and biophysical research communications
  34. Combating drug resistance in hepatocellular carcinoma: No awareness today, no action tomorrow.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  35. Long noncoding RNA HULC regulates the NF-κB pathway and represents a promising prognostic biomarker in liver cancer.2023Cancer medicineFree full text
  36. Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma.2023Cancer medicineFree full text
  37. Latrogenic Cerebral Infarction: A Rare but Sever Complication Caused by Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma.2023Cardiovascular and interventional radiology
  38. HBV-integrated local genomic alterations reveal multicentric independent occurrences of multifocal HCC.2023Clinical and translational medicineFree full text
  39. Incremental value of radiomics-based heterogeneity to the existing risk criteria in predicting recurrence of hepatocellular carcinoma after liver transplantation.2023European radiology
  40. Transmembrane serine protease 2 cleaves nidogen 1 and inhibits extrahepatic liver cancer cell migration and invasion.2023Experimental biology and medicine (Maywood, N.J.)Free full text
  41. The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  42. Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  43. Frizzled-3 suppression overcomes multidrug chemoresistance by Wnt/β-catenin signaling pathway inhibition in hepatocellular carcinoma cells.2023Journal of chemotherapy (Florence, Italy)
  44. Downregulation of ZC3H13 by miR-362-3p/miR-425-5p is associated with a poor prognosis and adverse outcomes in hepatocellular carcinoma.2022AgingFree full text
  45. Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.2022BMC cancerFree full text
  46. A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells.2022BMC cancerFree full text
  47. Prognostic Values of BolA Family Member Expression in Hepatocellular Carcinoma.2022BioMed research internationalFree full text
  48. RDIVpSGP motif of ASPP2 binds to 14-3-3 and enhances ASPP2/k18/14-3-3 ternary complex formulation to promote BRAF/MEK/ERK signal inhibited cell proliferation in hepatocellular carcinoma.2022Cancer gene therapy
  49. SOCS5 knockdown suppresses metastasis of hepatocellular carcinoma by ameliorating HIF-1α-dependent mitochondrial damage.2022Cell death & diseaseFree full text
  50. Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma.2022Cell death & diseaseFree full text
  51. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.2022Frontiers in immunologyFree full text
  52. The TTYH3/MK5 Positive Feedback Loop regulates Tumor Progression via GSK3-β/β-catenin signaling in HCC.2022International journal of biological sciencesFree full text
  53. Identification and validation of the N6-methyladenosine RNA methylation regulator ZC3H13 as a novel prognostic marker and potential target for hepatocellular carcinoma.2022International journal of medical sciencesFree full text
  54. Microwave ablation combined with I125 seed implantation for treatment of residual lesions of liver cancer after TACE.2022Journal of cancer research and therapeutics
  55. Preoperative Evaluation of Gd-EOB-DTPA-Enhanced MRI Radiomics-Based Nomogram in Small Solitary Hepatocellular Carcinoma (≤3 cm) With Microvascular Invasion: A Two-Center Study.2022Journal of magnetic resonance imaging : JMRI
  56. Hepatitis B virus (HBV) codon adapts well to the gene expression profile of liver cancer: an evolutionary explanation for HBV's oncogenic role.2022Journal of microbiology (Seoul, Korea)Free full text
  57. CT-Based Radiomics Nomogram: A Potential Tool for Differentiating Hepatocellular Adenoma From Hepatocellular Carcinoma in the Noncirrhotic Liver.2021Academic radiology
  58. Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma.2021BMC cancerFree full text
  59. Identification and validation of a novel immune-related signature associated with macrophages and CD8 T cell infiltration predicting overall survival for hepatocellular carcinoma.2021BMC medical genomicsFree full text
  60. Radiomics Analysis of MR Imaging with Gd-EOB-DTPA for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: Investigation and Comparison of Different Hepatobiliary Phase Delay Times.2021BioMed research internationalFree full text
  61. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.2021Biochemical and biophysical research communications
  62. Type IIA topoisomerase (TOP2A) triggers epithelial-mesenchymal transition and facilitates HCC progression by regulating Snail expression.2021BioengineeredFree full text
  63. Overexpression of ADAM9 decreases radiosensitivity of hepatocellular carcinoma cell by activating autophagy.2021BioengineeredFree full text
  64. Decreased expression of ARID1A invasively downregulates the expression of ribosomal proteins in hepatocellular carcinoma.2021Biomarkers in medicine
  65. The role of CD133 in hepatocellular carcinoma.2021Cancer biology & therapyFree full text
  66. Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance.2021Cancer letters
  67. Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis.2021Clinics and research in hepatology and gastroenterology
  68. An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation.2021European journal of nuclear medicine and molecular imaging
  69. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma.2021Journal of cellular and molecular medicineFree full text
  70. LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.2021Molecular and cellular biochemistry
Chinese-language papers (not in the count)1
  1. [Establishment and validation of a preoperative nomogram model for predicting the risk of hepatocellular carcinoma with microvascular invasion].2023Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status10
  1. Neutrophil Extracellular Traps as a Biomarker to Predict Portal Vein Tumor Thrombosis in Patients With Hepatocellular CarcinomaCompletedNCT05040347Lead sponsorStart 2020-08
  2. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07
  3. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal HypertensionNot yet recruitingNCT07350070Study sitePhase 2Start 2025-12
  4. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Study siteN/AStart 2025-06
  5. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Study sitePhase 2Start 2021-01
  6. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  7. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  8. A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB PatientsStatus unknownNCT05671315Study siteN/AStart 2019-07
  9. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04
  10. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 105 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.

Papers led
105
2021–2025
Trials led
19
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 191920212022: 191920222023: 171720232024: 191920242025: 30302025

2 hospitals in Qingdao for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 15

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07708012

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  2. Recruiting
    TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07714980

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 5 listed hospitals as study sitesBeijing, Qingdao, Weifang, Weihai, Yantai

  3. Recruiting
    TEAS for Gastrectomy Recovery
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT07898293

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 2 listed hospitals as study sitesQingdao, Weifang, Yantai

  4. Recruiting
    A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer
    Phase
    N/A
    Started
    2023-07
    Registry
    NCT06042998

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  5. Recruiting
    Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05871099

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  6. Not yet recruiting
    Home-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07764523

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  7. Not yet recruiting
    Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07183358

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  8. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  9. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  10. Recruiting
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06221748

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou

  11. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou

  12. Recruiting
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06730373

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong University; 7 listed hospitals as study sitesJinan, Linyi, Qingdao, Yantai, Zhengzhou, Zibo

  13. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  14. Not yet recruiting
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07902596

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou

  15. Not yet recruiting
    Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
    Phase
    Phase 4
    Started
    2024-07
    Registry
    NCT05498766

    Age 18 years to 75 years (registered criteria)

    Led by Union Hospital; 1 listed hospital as study siteQingdao, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryImaging & AIChemotherapy & combined treatment
Departments in papersMedical oncologyGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led105
  1. Mitochondrial uncoupling sensitizes gastric cancer cells to elesclomol-induced cuproptosis via FDX1/DLAT upregulation.2026Free radical biology & medicine
  2. CT-based radiomics model for predicting perineural invasion status in gastric cancer.2025Abdominal radiology (New York)
  3. Longitudinal CT Radiomics to Predict Progression-free Survival in Patients with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.2025Academic radiology
  4. An Integrated Radiopathomics Machine Learning Model to Predict Pathological Response to Preoperative Chemotherapy in Gastric Cancer.2025Academic radiology
  5. Three-year Survival Outcomes of Patients With Enhanced Recovery After Surgery Versus Conventional Care in Laparoscopic Distal Gastrectomy: The GISSG1901 Randomized Clinical Trial.2025Annals of surgeryRCTFree full text
  6. Identification and Categorization of Technical Errors and Hazard Zones of Robotic Versus Laparoscopic Total Gastrectomy for Gastric Cancer: A Single-center Prospective Randomized Controlled Study.2025Annals of surgeryRCTFree full text
  7. Effect of perioperative probiotic supplements on the short-term clinical outcomes of patients undergoing laparoscopic or robotic radical gastrectomy after neoadjuvant chemotherapy: Study protocol for a multicenter randomized controlled tria2025BMC cancerFree full text
  8. Diagnosis model for gastric submucosal tumor based on multiple decision trees comprising endoscopic and endoscopic ultrasonography features.2025BMC gastroenterologyFree full text
  9. Endoscopic resection of a giant broad-based gastric lipoma in an adolescent: a case report and literature review.2025BMC pediatricsFree full text
  10. Prognostic model for early gastric cardia cancer after endoscopic submucosal dissection.2025BMC surgeryFree full text
  11. Gastric Signet Ring Cell Carcinoma in a Helicobacter pylori-Positive 10-Year-Old Boy: A Case Report and Literature Review.2025Cancer scienceFree full text
  12. Developing a predictive model for delayed healing of esophagojejunal anastomotic fistula following total gastrectomy based on imaging and clinical inflammatory-nutritional status.2025Clinical nutrition ESPEN
  13. Predicting peritoneal recurrence and hyperthermic intraperitoneal chemotherapy benefits in T4 gastric cancer patients via contrast-enhanced CT radiomics.2025European journal of radiology
  14. Multimodal prehabilitation to improve functional abilities and reduce the chronic inflammatory response of frail elderly patients with gastric cancer: A prospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  15. Short- and long-term outcomes following perioperative ERAS management in patients undergoing minimally invasive radical gastrectomy after neoadjuvant chemotherapy: A single-center retrospective propensity score matching study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  16. Risk factors for lymph node metastasis and survival: Toward better endoscopic selection in ulcerative versus nonulcerative early gastric cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  17. Exceptional response to chemo-immunotherapy in a patient with HER2-negative, TMB-high metastatic gastric mucinous adenocarcinoma: a case report and literature review.2025Frontiers in immunologyFree full text
  18. Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer.2025Frontiers in immunologyFree full text
  19. Combination of cadonilimab (PD-1/CTLA-4 bispecific antibody) and apatinib as salvage therapy achieves partial response in MSI-H advanced gastric cancer: a case report.2025Frontiers in immunologyFree full text
  20. Short-term outcomes of preoperative computed tomography angiography versus standard assessment in patients with BMI ≥ 25.0 kg/m2 undergoing laparoscopic gastrectomy: the GISSG20-01 randomized clinical trial.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCT
  21. Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study.2025Human vaccines & immunotherapeuticsFree full text
  22. Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases.2025Human vaccines & immunotherapeuticsFree full text
  23. Integrating single-cell RNA sequencing and spatial transcriptomics to reveal the Glycolysis-related gene GPRC5A as a potential biomarker for gastric cancer by machine learning.2025International journal of biological macromolecules
  24. Retrospective study of the characteristics of early gastric cancer with surrounding map-like redness after successful Helicobacter pylori eradication.2025Journal of cancer research and therapeutics
  25. Application of computed tomography body composition in patients with locally progressive gastric cancer undergoing radical surgery combined with prophylactic hyperthermic intraperitoneal chemotherapy.2025Nutrition (Burbank, Los Angeles County, Calif.)
  26. Gastric duplication cysts with mixed hemangioma treated by endoscopic submucosal dissection: A case report and literature review.2025Pathology, research and practice
  27. Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K/AKT/mTOR-PD-L1 axis to overcome immune escape in gastric cancer.2025PeerJFree full text
  28. A nomogram for predicting non-curative resection in patients with early gastric cancer based on white light imaging.2025Scientific reportsFree full text
  29. Comparison of short- and long-term outcomes of robotic versus laparoscopic gastrectomy for locally advanced gastric cancer after neoadjuvant therapy: a high-volume center retrospective study with propensity score matching.2025Surgical endoscopy
  30. The Role of Patient-Controlled Epidural Analgesia in the Short-Term Outcomes of Laparoscopic-Assisted Gastrectomy in Elderly Gastric Cancer Patients.2025The Journal of surgical research
  31. Multi-omics integration reveals gut Microbiome and Short-chain fatty acid profiles in gastric cancer cachexia patients and their clinical significance.2025World journal of microbiology & biotechnology
  32. Tumor-Derived Exosomal LINC01480 Upregulates VCAM1 Expression by Acting as a Competitive Endogenous RNA of miR-204-5p to Promote Gastric Cancer Progression.2024ACS biomaterials science & engineering
  33. ASO Author Reflections: Deep-Learning Radiomics Nomogram Based on Enhanced CT to Predict the Effect of Neoadjuvant Chemotherapy on Metastatic Lymph Nodes in Locally Advanced Gastric Cancer.2024Annals of surgical oncology
  34. Deep Learning Radiomics Nomogram Based on Enhanced CT to Predict the Response of Metastatic Lymph Nodes to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.2024Annals of surgical oncology
  35. Integrating Tumor and Nodal Radiomics to Predict the Response to Neoadjuvant Chemotherapy and Recurrence Risk for Locally Advanced Gastric Cancer.2024Current medical imaging
  36. Short- and long-term comparison of robotic versus laparoscopic gastrectomy for gastric cancer patients with BMI≥30 kg/m2: A propensity score matched analysis.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  37. HIGD1B, as a novel prognostic biomarker, is involved in regulating the tumor microenvironment and immune cell infiltration; its overexpression leads to poor prognosis in gastric cancer patients.2024Frontiers in immunologyFree full text
  38. Development and verification of a manganese metabolism- and immune-related genes signature for prediction of prognosis and immune landscape in gastric cancer.2024Frontiers in immunologyFree full text
  39. Progressions of the correlation between lipid metabolism and immune infiltration characteristics in gastric cancer and identification of BCHE as a potential biomarker.2024Frontiers in immunologyFree full text
  40. Limitations of the cox proportional hazards model and alternative approaches in metachronous recurrence research.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  41. Development of oxidative stress- and ferroptosis-related prognostic signature in gastric cancer and identification of CDH19 as a novel biomarker.2024Human genomicsFree full text
  42. An investigation of the molecular characterization of the tripartite motif (TRIM) family and primary validation of TRIM31 in gastric cancer.2024Human genomicsFree full text
  43. Impact and effect of preoperative short-term preoperative pulmonary-related training on patients with gastric cancer: a randomized controlled single center trial.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCT
  44. Prediction of CD8+T lymphocyte infiltration levels in gastric cancer from contrast-enhanced CT and clinical factors using machine learning.2024Medical physics
  45. Somatic mutations that affect early genetic progression and immune microenvironment in gastric carcinoma.2024Pathology, research and practice
  46. Cepharanthine sensitizes gastric cancer cells to chemotherapy by targeting TRIB3-FOXO3-FOXM1 axis to inhibit autophagy.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  47. Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS.2024Scientific reportsFree full text
  48. Nortriptyline hydrochloride, a potential candidate for drug repurposing, inhibits gastric cancer by inducing oxidative stress by triggering the Keap1-Nrf2 pathway.2024Scientific reportsFree full text
  49. Neoadjuvant PD-(L)1 blockade with or without chemotherapy versus chemotherapy alone in mismatch repair-deficient, potentially resectable stage III-IVA gastric cancer patients: a single-center retrospective study.2024World journal of surgical oncologyFree full text
  50. Effect of preoperative immunonutrition on postoperative short-term clinical outcomes in patients with gastric cancer cachexia: a prospective randomized controlled trial.2024World journal of surgical oncologyRCTFree full text
  51. Quantitative Radiological Features and Deep Learning for the Non-Invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: A Digital Biopsy Study.2023Academic radiology
  52. Development a m6A regulators characterized by the immune cell infiltration in stomach adenocarcinoma for predicting the prognosis and immunotherapy response.2023AgingFree full text
  53. Characteristic analysis of early gastric cancer after Helicobacter pylori eradication: a multicenter retrospective propensity score-matched study.2023Annals of medicineFree full text
  54. Development and validation of nomograms for predicting overall survival and cancer-specific survival in elderly patients with locally advanced gastric cancer: a population-based study.2023BMC gastroenterologyRCTFree full text
  55. Multimodal prehabilitation to improve the clinical outcomes of frail elderly patients with gastric cancer: a study protocol for a multicentre randomised controlled trial (GISSG+2201).2023BMJ openFree full text
  56. Intraoperative performance and outcomes of robotic and laparoscopic total gastrectomy for gastric cancer: A high-volume center retrospective propensity score matching study.2023Cancer medicineFree full text
  57. Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer.2023Cancer scienceFree full text
  58. Systemic immune-inflammation index in predicting non-curative resection of endoscopic submucosal dissection in patients with early gastric cancer.2023European journal of gastroenterology & hepatologyFree full text
  59. A web-based prediction model for long-term cancer-specific survival of middle-aged patients with early-stage gastric cancer: a multi-institutional retrospective study.2023Journal of cancer research and clinical oncologyFree full text
  60. Prognostic Analysis of Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: a Propensity Score-Matched Analysis.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  61. Immunotherapy Efficacy-related Risk Classifier Differentiate Prognostic Characteristics of Gastric Cancer-A Large-scale Retrospective Study.2023Journal of immunotherapy (Hagerstown, Md. : 1997)
  62. A Modified Purse-String Stapling Technique for Intracorporeal Circular Stapled Esophagojejunostomy During Laparoscopic Total Gastrectomy: Comparison with Extracorporeal Reconstruction Technique.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  63. Diagnosis and treatment of gastric hamartomatous inverted polyp (GHIP) by endoscopic submucosal dissection: A case report.2023MedicineFree full text
  64. The Predictive Value of a New Inflammatory-Nutritional Score for Quality of Life after Laparoscopic Distal Gastrectomy for Gastric Cancer.2023Nutrition and cancer
  65. Gastric duplication cysts: literature review and a case report of rare multiple gastric duplication cysts treated by endoscopic submucosal dissection.2023Postgraduate medicine
  66. Short- and long-term outcomes of laparoscopic or robotic radical gastrectomy based on preoperative perigastric artery CTA surgical decision-making: a high-volume center retrospective study with propensity score matching.2023Surgical endoscopy
  67. Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis.2023Surgical endoscopy
  68. Randomized Controlled Trial Comparing the Short-term Outcomes of Enhanced Recovery After Surgery and Conventional Care in Laparoscopic Distal Gastrectomy (GISSG1901).2022Annals of surgeryRCTFree full text
  69. Metabolism reprogramming signature associated with stromal cells abundance in tumor microenvironment improve prognostic risk classification for gastric cancer.2022BMC gastroenterologyFree full text
  70. SLC6A14 Depletion Contributes to Amino Acid Starvation to Suppress EMT-Induced Metastasis in Gastric Cancer by Perturbing the PI3K/AKT/mTORC1 Pathway.2022BioMed research internationalFree full text
  71. LncRNA PVT1 Promotes Cell Proliferation, Invasion, and Migration and Inhibits Cell Apoptosis by Phosphorylating YAP.2022Canadian journal of gastroenterology & hepatologyFree full text
  72. Pyroptosis, apoptosis, and necroptosis molecular subtype derived prognostic signature universal applicable for gastric cancer-A large sample and multicenter retrospective analysis.2022Computers in biology and medicine
  73. Multiplex Accelerated PCR System for One-Step Helicobacter pylori cagA + Genotypes Detection: A Guide for Clinical Testing.2022Current microbiology
  74. A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options.2022Experimental and molecular pathology
  75. The Ferroptosis Molecular Subtype Reveals Characteristics of the Tumor Microenvironment, Immunotherapeutic Response, and Prognosis in Gastric Cancer.2022International journal of molecular sciencesFree full text
  76. A retrospective analysis of 13 cases of gastritis cystica profunda treated by endoscopic resection and surgery.2022Journal of digestive diseases
  77. The FOXO family of transcription factors: key molecular players in gastric cancer.2022Journal of molecular medicine (Berlin, Germany)
  78. Characteristics and background mucosa status of early gastric cancer after Helicobacter pylori eradication: A narrative review.2022MedicineFree full text
  79. Effect of endoscopic resection of gastrointestinal stromal tumors in the stomach under double-channel gastroscopy: A retrospective observational study.2022MedicineFree full text
  80. Ferroptosis‑related long non‑coding RNAs and the roles of LASTR in stomach adenocarcinoma.2022Molecular medicine reportsFree full text
  81. Effect of perioperative probiotic supplements on postoperative short-term outcomes in gastric cancer patients receiving neoadjuvant chemotherapy: A double-blind, randomized controlled trial.2022Nutrition (Burbank, Los Angeles County, Calif.)RCT
  82. LncRNA FGD5-AS1 drives the malignant development of gastric cancer by negatively interacting with FZD3.2022Polish journal of pathology : official journal of the Polish Society of Pathologists
  83. Short- and long-term comparison of robotic and laparoscopic gastrectomy for gastric cancer by the same surgical team: a propensity score matching analysis.2022Surgical endoscopy
  84. Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma.2022The oncologistFree full text
  85. LMP2A inhibits the expression of KLF5 through the mTORC1 pathway in EBV-associated gastric carcinoma.2022Virus research
  86. Integrated analysis of 1804 samples of six centers to construct and validate a robust immune-related prognostic signature associated with stromal cell abundance in tumor microenvironment for gastric cancer.2022World journal of surgical oncologyFree full text
  87. E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer.2021AgingFree full text
  88. Risk of Lymph Node Metastasis and Feasibility of Endoscopic Treatment in Ulcerative Early Gastric Cancer.2021Annals of surgical oncologyFree full text
  89. Correlations between CD4+ FoxP3+ Treg and expression of FoxM1 and Ki-67 in gastric cancer patients.2021Asia-Pacific journal of clinical oncology
  90. Application of three-dimensional reconstruction with a Hisense computer-assisted system in upper pancreatic lymph node dissection during laparoscopic-assisted radical gastrectomy.2021Asian journal of surgery
  91. 5-Fluorouracil enhances the chemosensitivity of gastric cancer to TRAIL via inhibition of the MAPK pathway.2021Biochemical and biophysical research communications
  92. ELK4-mediated lncRNA SNHG22 promotes gastric cancer progression through interacting with EZH2 and regulating miR-200c-3p/Notch1 axis.2021Cell death & diseaseFree full text
  93. Eight-gene prognostic signature associated with hypoxia and ferroptosis for gastric cancer with general applicability.2021Epigenomics
  94. Impact of drinking Chinese green tea on postoperative short outcomes for gastric cancer: a randomized controlled trial.2021European journal of clinical nutritionRCTFree full text
  95. Identification and Analysis of Key Genes Driving Gastric Cancer Through Bioinformatics.2021Genetic testing and molecular biomarkers
  96. microRNA-486-5p functions as a tumor suppressor in gastric carcinoma via directly targeting KDM5B.2021Journal of biological regulators and homeostatic agents
  97. HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma.2021Journal of cancer research and clinical oncologyFree full text
  98. FOXO3a-dependent Parkin regulates the development of gastric cancer by targeting ATP-binding cassette transporter E1.2021Journal of cellular physiology
  99. Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer.2021Journal of immunology researchFree full text
  100. Eleven immune-gene pairs signature associated with TP53 predicting the overall survival of gastric cancer: a retrospective analysis of large sample and multicenter from public database.2021Journal of translational medicineFree full text
  101. Silencing Ribosomal Protein L22 Promotes Proliferation and Migration, and Inhibits Apoptosis of Gastric Cancer Cells by Regulating the Murine Double Minute 2-Protein 53 (MDM2-p53) Signaling Pathway.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  102. Bioinformatic analysis of potential hub genes in gastric adenocarcinoma.2021Science progressFree full text
  103. Enhanced Recovery after Surgery in Elderly Gastric Cancer Patients Undergoing Laparoscopic Total Gastrectomy.2021The Journal of surgical researchRCT
  104. Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial.2021The oncologistFree full text
  105. LMP2A suppresses the role of AHR pathway through ERK signal pathway in EBV-associated gastric cancer.2021Virus research
Chinese-language papers (not in the count)3
  1. [Practical exploration on the responsibilities and operation specifications of assistants in robotic radical gastrectomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Technical challenges and preventive countermeasures of robotic gastric cancer surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Changes in tumor microbiome and underlying value according to response to neoadjuvan chemotherapy for in patients with gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status44
  1. Home-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile HealthNot yet recruitingNCT07764523Lead sponsorN/AStart 2026-08
  2. TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)RecruitingNCT07714980Lead sponsorN/AStart 2026-07
  3. Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric CancerNot yet recruitingNCT07183358Lead sponsorN/AStart 2025-09
  4. TEAS for Gastrectomy RecoveryRecruitingNCT07898293Lead sponsorN/AStart 2024-10
  5. A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric CancerRecruitingNCT06042998Lead sponsorN/AStart 2023-07
  6. Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or NotRecruitingNCT05871099Lead sponsorPhase 3Start 2022-11
  7. Carina™ Surgical Platform for Minimal Radical GastrectomyActive, not recruitingNCT07113340Lead sponsorN/AStart 2025-05
  8. Prehabilitation Plus ERAS in Gastric Cancer SurgeryCompletedNCT07328633Lead sponsorN/AStart 2024-12
  9. Whole Course Multi-model Prehabilitation to Improve Clinical Outcome in Patients Undergoing Neoadjuvant Treatment Prior to GastrectomyStatus unknownNCT06521541Lead sponsorN/AStart 2024-06
  10. Effect of Probiotic Supplements on Gastric Cancer Patients Receiving Neoadjuvant ChemotherapyStatus unknownNCT05901779Lead sponsorN/AStart 2023-04
  11. ERAS for Gastric Cancer Patients After NACTCompletedNCT06365814Lead sponsorStart 2023-10
  12. Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing TrialStatus unknownNCT05952375Lead sponsorN/AStart 2023-03
  13. Effects of Omega-3 Fish Oil Fat Emulsion on Rehabilitation and Immune Function After Radical Surgery Combined With Intraperitoneal Hyperthermic Infusion Chemotherapy in Patients With Locally Advanced Gastric CancerStatus unknownNCT06047158Lead sponsorStart 2022-12
  14. Quantitative Detection of CEA mRNA in the Smog and Tissue Exudate Whole Process Collected During Laparoscopic (Robotic) Radical Gastrectomy in Gastric Cancer PatientsStatus unknownNCT06076265Lead sponsorStart 2022-12
  15. Multimodal Prehabilitation To Improve The Clinical Outcomes Of Frail Elderly Patients With Gastric CancerActive, not recruitingNCT05352802Lead sponsorN/AStart 2022-09
  16. Gastrointestinal Surgery Study Group 2001Status unknownNCT04636099Lead sponsorN/AStart 2020-11
  17. Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)Status unknownNCT04713059Lead sponsorStart 2020-01
  18. Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric CancerRecruitingNCT07708012Lead (inferred)N/AStart 2026-01
  19. Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative OutcomeCompletedNCT02649348Lead (inferred)N/AStart 2015-09
  20. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  21. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ AdenocarcinomaNot yet recruitingNCT07902596Study siteStart 2026-10
  22. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Study sitePhase 2Start 2025-12
  23. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  24. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Study sitePhase 2/Phase 3Start 2024-02
  25. Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer PatientsNot yet recruitingNCT05498766Study sitePhase 4Start 2024-07
  26. First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingNCT06730373Study sitePhase 2Start 2024-10
  27. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  28. Postoperative Adjuvant Therapy for Stage II-III Gastric CancerActive, not recruitingNCT06609759Study siteStart 2024-01
  29. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  30. Minimal Residual Disease-guided Adjuvant Therapy for Gastric CancerActive, not recruitingNCT06157216Study siteN/AStart 2023-10
  31. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Study sitePhase 2Start 2023-02
  32. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Study sitePhase 2Start 2023-03
  33. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  34. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  35. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  36. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  37. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  38. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  39. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  40. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  41. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  42. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  43. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Study sitePhase 2Start 2018-07
  44. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 6 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 3.9%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 442025

1 hospital in Qingdao for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led6
  1. A Novel Visual Model for Predicting Prognosis of Resected Hepatoblastoma: A Multicenter Study.2025Academic radiology
  2. Exploring the role of LFNG in hepatoblastoma using multiomics and raise a query in proof link.2025Gene
  3. Intratumoral Heterogeneity and Immune Microenvironment in Hepatoblastoma Revealed by Single-Cell RNA Sequencing.2025Journal of cellular and molecular medicine
  4. LncRNA938/ TAF9/TTK axis promotes EMT and serves as a therapeutic target in hepatoblastoma.2025Journal of translational medicine
  5. A Novel Method for Observing Tumor Margin in Hepatoblastoma Based on Microstructure 3D Reconstruction.2022Fetal and pediatric pathology
  6. Analysis of survival rates and prognosis of hepatoblastoma in children: a retrospective study from a single center in China.2021Pediatric hematology and oncology
Earlier papers (2016–2020)3
  1. Imaging and Pathology Study of the Chemotherapy Regression Area of Hepatoblastoma - A Prospective Single-Center Study.2020Fetal and pediatric pathology
  2. Comparison between infantile hepatic hemangioendothelioma and hepatoblastoma in pediatric patients: clinical manifestations and contrast-enhanced computed tomography features.2018Minerva pediatrica
  3. Usefulness of three-dimensional(3D) simulation software in hepatectomy for pediatric hepatoblastoma.2016Surgical oncology
All its trials on ClinicalTrials.gov, any status1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Qingdao for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Qingdao for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Role of extracellular matrix in chordoma progression and therapeutic resistance.2026Critical reviews in oncology/hematology
Earlier papers (2016–2020)1
  1. Intradural cervical chordoma with diffuse spinal leptomeningeal spread: case report and review of the literature.2018European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 16 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 2220232024: 4420242025: 442025

7 hospitals in Qingdao for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led16
  1. Spikey biodegradable MXene nanosheets with enhanced cellular internalization and stimuli-responsive drug delivery for synergistic cancer therapy.2025Journal of nanobiotechnology
  2. Multi-omics and Single Cell Sequencing Analyses Reveal Associations of Mitophagy-Related Genes Predicting Clinical Prognosis and Immune Infiltration Characteristics in Osteosarcoma.2025Molecular biotechnology
  3. Butyrate derived from intratumoral microbiome facilitates pulmonary metastasis in osteosarcoma.2025Pharmacological research
  4. Lumbar Extradural Extraskeletal Ewing Sarcoma with Psoas Denervation: A Case Report.2025The American journal of case reports
  5. Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma.2024Biochimica et biophysica acta. Reviews on cancer
  6. Inhibition of anlotinib-induced autophagy attenuates invasion and migration by regulating epithelial-mesenchymal transition and cytoskeletal rearrangement through ATG5 in human osteosarcoma cells.2024Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  7. Ct-based intratumoral and peritumoral radiomics for predicting prognosis in osteosarcoma: A multicenter study.2024European journal of radiology
  8. Schottky heterojunction CeO2@MXene nanosheets with synergistic type I and type II PDT for anti-osteosarcoma.2024Journal of materials chemistry. B
  9. Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma.2023Anticancer research
  10. Zeolitic Imidazolate Framework (ZIF-8) Decorated Iron Oxide Nanoparticles Loaded Doxorubicin Hydrochloride for Osteosarcoma Treatment - in vitro and in vivo Preclinical Studies.2023International journal of nanomedicine
  11. Knocking down Siglec-15 in osteosarcoma cells inhibits proliferation while promoting apoptosis and pyroptosis by targeting the Siglec-15/STAT3/Bcl-2 pathway.2022Advances in medical sciences
  12. Extraperitoneal Laparoscopic Radical Cystectomy With Preservation of Fertility for the Treatment of Ewing Sarcoma: The First Report of a Reliable Surgical Method.2022Urology
  13. Establishment of an Autophagy-Related Clinical Prognosis Model for Predicting the Overall Survival of Osteosarcoma.2021BioMed research international
  14. Risk Factors, Prognostic Factors, and Nomograms for Distant Metastasis in Patients With Newly Diagnosed Osteosarcoma: A Population-Based Study.2021Frontiers in endocrinology
  15. Nasopharyngeal carcinoma‑associated gene 6 inhibits cell viability, migration, invasion and induces apoptosis in osteosarcoma cells by inactivating the Wnt/β‑catenin signaling pathway.2021Molecular medicine reports
  16. THAP9-AS1 Promotes Tumorigenesis and Reduces ROS Generation through the JAK2/STAT3 Signaling Pathway by Increasing SOCS3 Promoter Methylation in Osteosarcoma.2021Oxidative medicine and cellular longevity
Earlier papers (2016–2020)29
  1. MNAT1 promotes proliferation and the chemo-resistance of osteosarcoma cell to cisplatin through regulating PI3K/Akt/mTOR pathway.2020BMC cancer
  2. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.2020BMC cancer
  3. PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma.2020Biochemical and biophysical research communications
  4. Circular RNA circ_0000337 contributes to osteosarcoma via the miR-4458/BACH1 pathway.2020Cancer biomarkers : section A of Disease markers
  5. PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells.2020Clinical & experimental metastasis
  6. Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells.2020Current pharmaceutical biotechnology
  7. ADAMTS7 degrades Comp to fuel BMP2-dependent osteogenic differentiation and ameliorate oncogenic potential in osteosarcomas.2020FEBS open bio
  8. MicroRNA-197 inhibits the progression of osteosarcoma through targeting FOXM1.2020Minerva endocrinologica
  9. Osteosarcoma and Epidermoid Cyst in the Cerebellopontine Angle of an Adult.2020World neurosurgery
  10. LncRNA HIF1A-AS2 promotes osteosarcoma progression by acting as a sponge of miR-129-5p.2019Aging
  11. Targeting XIST induced apoptosis of human osteosarcoma cells by activation of NF-kB/PUMA signal.2019Bioengineered
  12. sCLU as prognostic biomarker and therapeutic target in osteosarcoma.2019Bioengineered
  13. Clinical importance of S100A9 in osteosarcoma development and as a diagnostic marker and therapeutic target.2019Bioengineered
  14. Circular RNA hsa_circ_0000885 Levels are Increased in Tissue and Serum Samples from Patients with Osteosarcoma.2019Medical science monitor : international medical journal of experimental and clinical research
  15. SND1 promotes the proliferation of osteosarcoma cells by upregulating COX‑2/PGE2 expression via activation of NF‑κB.2019Oncology reports
  16. Hsa_circ_0009910 promotes carcinogenesis by promoting the expression of miR-449a target IL6R in osteosarcoma.2018Biochemical and biophysical research communications
  17. Astragalus polysaccharides decrease proliferation, migration, and invasion but increase apoptosis of human osteosarcoma cells by up-regulation of microRNA-133a.2018Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  18. Serum miR-542-3p as a prognostic biomarker in osteosarcoma.2018Cancer biomarkers : section A of Disease markers
  19. Long non-coding RNA PVT1 promotes glycolysis and tumor progression by regulating miR-497/HK2 axis in osteosarcoma.2017Biochemical and biophysical research communications
  20. miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal.2017Cancer biomarkers : section A of Disease markers
  21. PTEN Plays Dual Roles As a Tumor Suppressor in Osteosarcoma Cells.2017Journal of cellular biochemistry
  22. Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line.2017Molecular medicine reports
  23. Combined analysis of gene expression, miRNA expression and DNA methylation profiles of osteosarcoma.2017Oncology reports
  24. Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway.2017Oncotarget
  25. miR-21 predicts poor prognosis in patients with osteosarcoma.2016British journal of biomedical science
  26. miR-497 as a potential serum biomarker for the diagnosis and prognosis of osteosarcoma.2016European review for medical and pharmacological sciences
  27. Targeting miR-29 induces apoptosis of osteosarcoma MG-63 cells via regulation of TGF-β1/PUMA signal.2016European review for medical and pharmacological sciences
  28. Primary Cardiac Osteosarcoma.2016Heart, lung & circulation
  29. Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis.2016Journal of orthopaedic surgery and research

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 7 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 1120242025: 332025

3 hospitals in Qingdao for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Pediatrics
Papers it led7
  1. Diagnosis model for gastric submucosal tumor based on multiple decision trees comprising endoscopic and endoscopic ultrasonography features.2025BMC gastroenterologyFree full text
  2. Feasibility and safety of endoscopic full-thickness resection for submucosal tumors in the upper gastrointestinal tract, including predominantly extraluminal submucosal tumors (with video).2025Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  3. Merged gastrointestinal stromal tumor, intestinal obstruction, and perforation in Meckel's diverticulum: Case report.2025Medicine
  4. Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution.2024Cell death & disease
  5. Value of contrast-enhanced CT based radiomic machine learning algorithm in differentiating gastrointestinal stromal tumors with KIT exon 11 mutation: a two-center study.2022Diagnostic and interventional radiology (Ankara, Turkey)
  6. An artificial intelligence system for distinguishing between gastrointestinal stromal tumors and leiomyomas using endoscopic ultrasonography.2022Endoscopy
  7. Effect of endoscopic resection of gastrointestinal stromal tumors in the stomach under double-channel gastroscopy: A retrospective observational study.2022MedicineFree full text
Chinese-language papers (not in the count)1
  1. [Definition of tumor rupture in gastrointestinal stromal tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Earlier papers (2016–2020)5
  1. Prognostic Factors for Primary Localized Gastrointestinal Stromal Tumors After Radical Resection: Shandong Gastrointestinal Surgery Study Group, Study 1201.2020Annals of surgical oncology
  2. Long-term Outcomes of Endoscopic Resection for Gastric Subepithelial Tumors.2020Surgical laparoscopy, endoscopy & percutaneous techniques
  3. Comparison between laparoscopic and endoscopic resections for gastric submucosal tumors.2019Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  4. S100A4 expression is associated with poor prognosis in patients with resectable gastrointestinal stromal tumor.2019The Libyan journal of medicine
  5. [Analysis of gastric gastrointestinal stromal tumors in Shandong Province: a midterm report of multicenter GISSG1201 study].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status3
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  3. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 9 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 1120232024: 1120242025: 112025

6 hospitals in Qingdao for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsRheumatology & immunologyPathology / laboratory medicineENT / head & neck surgery

Over half of these papers are lab or animal studies.

Papers it led9
  1. TCF4 Promotes Neuroblastoma Proliferation and Inhibits Ferroptosis by Transactivating GPX4 Expression.2025Applied biochemistry and biotechnology
  2. Neuroprotective effects of polyphyllin VI against rotenone-induced toxicity in SH-SY5Y cells.2024Brain research
  3. Computer-assisted resection of multifocal primary neuroblastic tumors: A case report.2023Asian journal of surgery
  4. miR-21 Targets Long Noncoding RNA PCAT29 to Promote Cell Proliferation in Neuroblastoma.2022Critical reviews in eukaryotic gene expression
  5. Steroid treatment response combined with serological mark in differentiating type-1 autoimmune pancreatitis from pancreatic cancer.2022Medicine
  6. Potential use of bioactive nanofibrous dural substitutes with controlled release of IGF-1 for neuroprotection after traumatic brain injury.2022Nanoscale
  7. miRNA-34a-5p regulates progression of neuroblastoma via modulating the Wnt/β-catenin signaling pathway by targeting SOX4.2021Medicine
  8. Identification S100A9 as a potential biomarker in neuroblastoma.2021Molecular biology reports
  9. MYCN‑amplified neuroblastoma cell‑derived exosomal miR‑17‑5p promotes proliferation and migration of non‑MYCN amplified cells.2021Molecular medicine reports
Chinese-language papers (not in the count)1
  1. [Diagonistic and prognostic analysis of olfactory neuroblastoma].2021Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery
Earlier papers (2016–2020)11
  1. MicroRNA-145 overexpression inhibits neuroblastoma tumorigenesis in vitro and in vivo.2020Bioengineered
  2. Long noncoding RNA LINC01410 promotes the tumorigenesis of neuroblastoma cells by sponging microRNA-506-3p and modulating WEE1.2020Cancer medicine
  3. MicroRNA-429 inhibits neuroblastoma cell proliferation, migration and invasion via the NF-κB pathway.2020Cellular & molecular biology letters
  4. Inhibition of BAG-1 induced SH-SY5Y cell apoptosis without affecting Hsp70 expression.2020Journal of cellular biochemistry
  5. [A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma].2020Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  6. Picroside II Protects SH-SY5Y Cells From Autophagy and Apoptosis Following Oxygen Glucose Deprivation/Reoxygen Injury by Inhibiting JNK Signal Pathway.2019Anatomical record (Hoboken, N.J. : 2007)
  7. MiR-223-3p promotes the growth and invasion of neuroblastoma cell via targeting FOXO1.2019European review for medical and pharmacological sciences
  8. Role of SNHG7-miR-653-5p-STAT2 feedback loop in regulating neuroblastoma progression.2019Journal of cellular physiology
  9. Angelica sinensis polysaccharide inhibits proliferation, migration, and invasion by downregulating microRNA-675 in human neuroblastoma cell line SH-SY5Y.2018Cell biology international
  10. MiR-34-a acts as a suppressor in neuroblastoma progression by targeting CD44.2017JPMA. The Journal of the Pakistan Medical Association
  11. dl-3-n-Butylphthalide attenuation of methamphetamine-induced neurotoxicity in SH-SY5Y neuroblastoma cells.2016Life sciences
All its trials on ClinicalTrials.gov, any status1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

2 hospitals in Qingdao for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 8 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.5%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 332025

2 hospitals in Qingdao for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskKidney & bone complicationsBispecific & antibody drugs
Departments in papersPathology / laboratory medicineClinical trials / research unitRadiology / nuclear medicine
Papers it led8
  1. Deep learning and transformer-based feature fusion of conventional MRI for differentiating spinal osteolytic bone metastases and multiple myeloma.2026European journal of radiology
  2. Cyanidin-3-O-glucoside-mediated reduction of regulatory T cells: a therapeutic strategy for multiple myeloma.2025BMC immunologyFree full text
  3. Proportional and functional anomalies of CD38+ NK Cells:A new mechanism for impaired anti-tumour immunity in multiple myeloma?2025Immunobiology
  4. Primary Systemic Amyloidosis Characterized by Multiple Keratinous Cysts: A Case Report.2025Journal of cutaneous pathology
  5. Identification of HIST1H2BH as the hub gene associated with multiple myeloma using integrated bioinformatics analysis.2024Hematology (Amsterdam, Netherlands)
  6. DEPDC1B enhances malignant phenotypes of multiple myeloma through upregulating CCNB1 and inhibiting p53 signaling pathway.2024Tissue & cell
  7. Lumbar MR-based radiomics nomogram for detecting minimal residual disease in patients with multiple myeloma.2023European radiology
  8. Application of Capillary Electrophoresis in Monoclonal Gammopathies and the Cutoff Value of Monoclonal Protein in Differential Diagnosis of Multiple Myeloma and Other Monoclonal Gammopathies.2021Annals of clinical and laboratory science
Chinese-language papers (not in the count)4
  1. [Correlation between CRAB Symptoms and Antioxidant Enzyme Activity in Patients with Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
  2. [Light chain amyloidosis with cuticular cysts as the initial symptom complicated with multiple myeloma: report of a case].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Application of MRI Water-Fat Separation Technology in Patients with Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status4
  1. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  4. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution

1 hospital in Qingdao for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
  1. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  2. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  3. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  4. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 7 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 1.7%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 2220242025: 222025

1 hospital in Qingdao for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantClonal evolution & PNHChildren

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

1 hospital in Qingdao for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesLymphoma & cancer-related HLHTreatment regimensStem cell transplant
Departments in papersMedical oncologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Qingdao for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Diagnostic Values of Inflammatory and Angiogenic Factors for Acute Joint Bleeding in Patients With Severe Hemophilia A.2020Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
All its trials on ClinicalTrials.gov, any status7
  1. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ANot yet recruitingNCT06136507Study sitePhase 3Start 2026-12
  2. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03
  3. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  4. A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionCompletedNCT05265286Study sitePhase 2Start 2022-04
  5. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  6. A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ,Fc Fusion Protein for InjectionCompletedNCT05251090Study sitePhase 1Start 2021-06
  7. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Qingdao for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Chinese-language papers (not in the count)2
  1. [Diagnosis, treatment, and genetic analysis of five cases of primary atypical hemolytic uremic syndrome].2025Zhonghua nei ke za zhi
  2. [Genetic analysis of a child with atypical Hemolytic uremic syndrome and nephrotic-range proteinuria].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Qingdao for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 1 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Qingdao for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07676266

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic drugsAcute attack treatmentAntibodies & diagnosis

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

1 hospital in Qingdao for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment & relapsePancreas & bile ducts
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

1 hospital in Qingdao for myasthenia gravis89 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07676266

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic & complement drugsStandard immunotherapyAntibodies & diagnosis

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

1 hospital in Qingdao for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRevascularisation surgeryImaging & blood flow
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 2 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Qingdao for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Diagnosis & copper tests
Departments in papersRheumatology & immunologyNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Qingdao for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

3 hospitals in Qingdao for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led3
  1. Diabetes mellitus and idiopathic pulmonary fibrosis: a Mendelian randomization study.2024BMC pulmonary medicine
  2. Mediastinal lymph node enlargement predicts progressive pulmonary fibrosis.2023The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  3. Disturbance of serum lipid metabolites and potential biomarkers in the Bleomycin model of pulmonary fibrosis in young mice.2022BMC pulmonary medicine
Earlier papers (2016–2020)3
  1. Comment on "Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis".2018Mediators of inflammation
  2. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.2017Pharmaceutical biology
  3. Acute exacerbation of idiopathic pulmonary fibrosis after total hip replacement.2016Journal of clinical anesthesia
All its trials on ClinicalTrials.gov, any status3
  1. Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed ConditionsCompletedNCT06569381Study sitePhase 1Start 2024-09
  2. Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed ConditionsCompletedNCT06588517Study sitePhase 1Start 2024-04
  3. Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed ConditionsCompletedNCT06589921Study sitePhase 1Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Qingdao for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led2
  1. Prevalence of Sialorrhea Among Amyotrophic Lateral Sclerosis Patients: A Systematic Review and Meta-Analysis.2022Journal of pain and symptom management
  2. NEK1 mutations and the risk of amyotrophic lateral sclerosis (ALS): a meta-analysis.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Earlier papers (2016–2020)2
  1. Association between TBK1 mutations and risk of amyotrophic lateral sclerosis/frontotemporal dementia spectrum: a meta-analysis.2018Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Distinct neurological disorders with C9orf72 mutations: genetics, pathogenesis, and therapy.2016Neuroscience and biobehavioral reviews

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Qingdao for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Qingdao for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Qingdao for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led 1 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Qingdao for Gaucher disease40 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led 1 of the 16 English-language PubMed papers on Niemann–Pick disease type C with an author in mainland China, 2021–2025: 6.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Qingdao for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Whole-exome sequencing analysis to identify novel potential pathogenetic NPC1 mutations in two Chinese families with Niemann-Pick disease type C.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 6 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 2.0%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 112025

2 hospitals in Qingdao for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRheumatology & immunology
Papers it led6
  1. Fibroblast growth factor 19 in combination with liver fibrosis markers for non-invasive diagnosis of primary biliary cholangitis-associated cirrhosis.2026Clinica chimica acta; international journal of clinical chemistry
  2. Vitamin D3 attenuates hepatic inflammation in primary biliary cholangitis by inhibiting TLR4/NF-κB mediated M1 macrophage polarization.2025Scientific reports
  3. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.2024Immunity, inflammation and disease
  4. Genetic association and causal relationship between multiple modifiable risk factors and autoimmune liver disease: a two-sample mendelian randomization study.2024Journal of translational medicine
  5. Effect of LncRNA XIST on Immune Cells of Primary Biliary Cholangitis.2022Frontiers in immunology
  6. Detection of anti-kelch-like 12 and anti-hexokinase 1 antibodies in primary biliary cholangitis patients in China.2021Revista espanola de enfermedades digestivas
Earlier papers (2016–2020)3
  1. Effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin on T Cell Differentiation in Primary Biliary Cholangitis.2020BioMed research international
  2. Serum vitamin D level is related to disease progression in primary biliary cholangitis.2020Scandinavian journal of gastroenterology
  3. Inflammatory Demyelinating Pseudotumor With Liver Dysfunction: IgG4 Related Disease With Primary Biliary Cholangitis.2020The American journal of the medical sciences
All its trials on ClinicalTrials.gov, any status1
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

1 hospital in Qingdao for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Rheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Qingdao for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Qingdao for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Qingdao for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led1
  1. Progress in diagnosis and treatment of Leber's hereditary optic neuropathy.2024Journal of molecular medicine (Berlin, Germany)

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

青岛大学附属医院

Affiliated Hospital of Qingdao University

青岛

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Affiliated Hospital of QingDao University; Affiliated Hospital of Qingdao University Medical College; Yantai Yuhuangding Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Qingdao University; Affiliated Hospital of Qingdao University and Qingdao Cancer Institute; Second Affiliated Hospital of Qingdao University Medical College

Suggest a correctionDownload the data